Roche Wins EU Approval for Susvimo in Neovascular AMD

Roche Holding AG (RHHBY) said the European Commission approved Susvimo (ranibizumab 100 mg/mL) for treating neovascular age-related macular degeneration in adults, per an announcement dated September 22, 2026. The approval covers the ranibizumab formulation delivered via the Susvimo ocular implant system, a refillable device designed for intravitreal administration, according to the company. Roche said the authorization applies across EU member states, expanding the company's ophthalmology portfolio into a major vision-loss indication.